Pancreatic Cancer¶
Chapter 88 | Pancreatic Cancer: Epidemiology, Pathophysiology, Diagnosis, and Management
KEY CLINICAL POINTS¶
- Pancreatic cancer is the third leading cause of cancer-related mortality in the U.S., with a 5-year survival rate of ~13% and projected to be the second leading cause of cancer death by 2030.
- Genetic predisposition accounts for 10–16% of cases, with BRCA2, p16/CDKN2A, and Lynch syndrome mutations conferring 3.5–140-fold increased risk.
- KRAS mutations (90–95% of cases) and microsatellite instability (MSI) are critical molecular drivers, with PARP inhibitors showing promise in BRCA/MLH1/MSH2/MSH6-deficient tumors.
- Early detection remains challenging, but neoadjuvant therapy and adjuvant FOLFIRINOX (median survival 54 months) improve outcomes for resectable disease.
- Metastatic disease is managed with FOLFIRINOX, gemcitabine, or NAPOLI-3 regimens, with 1-year survival improving to ~2 years in select cases.
1. DEFINITION & OVERVIEW¶
Pancreatic cancer is the most lethal human cancer, with an overall 5-year survival of 13%. It is classified as ductal adenocarcinoma (90% of cases) or neuroendocrine tumors (Chap. 89). Early detection is critical, with screening recommended for high-risk individuals (e.g., BRCA1/2 carriers) via MRI/ultrasound.
Table 88-1: Germline Mutations and Pancreatic Cancer Risk¶
| GERMLINE MUTATION | FAMILIAL CANCER SYNDROME | ESTIMATED INCREASED RISK (FOLD) |
|---|---|---|
| BRCA2a | Familial breast/ovarian cancer and others | 3.5–10 |
| p16/CDKN2A | Familial atypical multiple mole melanoma (FAMMM) | 15–22 |
| PRSS1 or SPIN11b | Hereditary pancreatitis | 53 |
| MLH1, MSH2, MSH6, PMS2 | Lynch syndrome | 9–36 |
1.1 Epidemiology¶
Accounts for 3% of all cancers in the U.S., ~8.3% of cancer deaths. Lifetime risk: 1.7%. Incidence rising 1.1%/year overall, 2.36%/year in women <55. 5-year survival: 13% (2024), with localized disease at 44%, regional at 16%, and metastatic at 3.2%.
1.2 Genetic Predisposition¶
Germline mutations in BRCA2, p16/CDKN2A, PRSS1, ATM, and Lynch syndrome genes increase risk. 10–16% of cases are hereditary. BRCA1/2 carriers benefit from PARP inhibitors in metastatic disease.
2. EPIDEMIOLOGY¶
Pancreatic cancer is the 11th most common cancer globally, with ~500,000 new cases/year. Mortality exceeds incidence in the U.S. (66,000 diagnosed, 51,000 deaths/year). Risk factors include age (median 71), male sex, non-O blood type, and smoking (25–30% of cases).
2.1 Demographics¶
More common in men than women, with incidence rising sharply in those <55. Black populations have higher incidence and mortality. 5-year survival increased from 3% (1975) to 13% (2024).
2.2 Environmental Risk Factors¶
Smoking (25–30% of cases), obesity (BMI ≥ 30 doubles risk), and chronic pancreatitis (2.3–16.5-fold risk). Diabetes mellitus (type 1/2) is associated with increased risk, though causality is unclear.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Genetic mutations (KRAS, p16/CDKN2A, TP53, SMAD4) and epigenetic changes drive 90–95% of cases. PanIN lesions (Pancreatic Intraepithelial Neoplasia) are precursor lesions, with grade 3 lesions progressing to invasive cancer. Microsatellite instability (MSI) occurs in 1% of cases due to mismatch repair defects.
3.1 Molecular Mechanisms¶
KRAS mutations (codon 12) in 90–95% of cases. p16/CDKN2A inactivation in 90% of invasive adenocarcinomas. TP53 mutations in 75%, SMAD4 in 50%. MSI in 1% of tumors with defective mismatch repair.
3.2 Precursor Lesions¶
PanINs (grades 1–3) and intraductal papillary mucinous neoplasms (IPMN) are precursor lesions. High-grade PanINs may progress to cancer, but are often undetectable by imaging.
4. CLINICAL FEATURES¶
Classic presentation: painless jaundice (bilirubin >2 mg/dL), pruritus, and weight loss. 15–20% present with diabetes mellitus or hyperglycemia. Physical signs include Courvoisier’s sign (palpable gallbladder), Trousseau’s syndrome (thrombophlebitis), and Virchow’s node (supraclavicular lymphadenopathy).
4.1 Symptomatology¶
Pain (mid-epigastric, radiating to back), steatorrhea, malabsorption, and weight loss. 10–15% present with diabetes mellitus or hyperglycemia. Depression is controversially associated.
4.2 Physical Findings¶
Courvoisier’s sign (biliary obstruction), Trousseau’s syndrome (thrombophlebitis), and Sister Mary Joseph’s node (periumbilical metastases).
5. DIFFERENTIAL DIAGNOSIS¶
Cholangitis, gallstones, pancreatic pseudocyst, and other biliary/pancreatic disorders. Differentiate from chronic pancreatitis, choledocholithiasis, and metastatic tumors to the pancreas.
5.1 Key Differentiators¶
Painless jaundice vs. cholangitis (painful), weight loss vs. malnutrition, and imaging findings (e.g., IPMN vs. adenocarcinoma).
6. INVESTIGATIONS & DIAGNOSIS¶
Imaging (CT/MRI with dual-phase contrast), serum markers (CA19-9, CEA), and histopathology. PET scans detect occult metastases. Molecular testing (KRAS, MSI, BRCA) guides targeted therapy.
Table 88-2: AJCC Staging Criteria¶
| T CATEGORY | T CRITERIA | N CATEGORY | N CRITERIA | M CATEGORY | M CRITERIA |
|---|---|---|---|---|---|
| T0 | No evidence of primary tumor | N0 | No regional lymph node metastases | M0 | No distant metastasis |
| Tis | Carcinoma in situ | N1 | Metastasis in 1–3 regional lymph nodes | M1 | Distant metastasis |
| T1 | Tumor £2 cm | N2 | Metastasis in ‡4 regional lymph nodes | ||
| T2 | Tumor >2 cm £4 cm | NX | Regional lymph nodes cannot be assessed | ||
| T3 | Tumor >4 cm | ||||
| T4 | Involves celiac axis, SMA, or hepatic artery |
6.1 Imaging¶
Contrast-enhanced CT (arterial/portal venous phases) for staging. MRI with endoscopic ultrasound (EUS) for small tumors. PET-CT detects metastases.
6.2 Laboratory Tests¶
CA19-9 (elevated in 70–80% of cases), CEA, and liver function tests. Monitor for hyperglycemia and malabsorption.
6.3 Histopathology¶
Tru-Cut biopsy or fine-needle aspiration (FNA). Molecular testing for KRAS, MSI, and germline variants (BRCA, Lynch syndrome).
7. MANAGEMENT & TREATMENT¶
Resectable disease: surgery (pancreaticoduodenectomy) + adjuvant FOLFIRINOX (median survival 54 mo). Locally advanced: neoadjuvant chemotherapy + surgery. Metastatic: FOLFIRINOX, gemcitabine, or PARP inhibitors (BRCA/MSI tumors).
Table 88-3: Extent of Disease and Therapeutic Approaches¶
| DESIGNATION (MEDIAN SURVIVAL) | THERAPEUTIC APPROACHES |
|---|---|
| Resectable (18–23 mo) | Surgery + adjuvant mFOLFIRINOX/gemcitabine |
| Locally advanced (6–18 mo) | Neoadjuvant chemotherapy + surgery (20% resectable) |
| Metastatic (6–12 mo) | FOLFIRINOX, gemcitabine, or PARP inhibitors (BRCA/MSI) |
7.1 Resectable Disease¶
Pancreaticoduodenectomy (Whipple procedure) with adjuvant FOLFIRINOX (modified) or gemcitabine. 5-year survival 50–90% for stage I tumors.
7.2 Locally Advanced Disease¶
Neoadjuvant chemotherapy (FOLFIRINOX) to downstage tumors. 20% may become resectable. Radiation may be used adjunctively.
7.3 Metastatic Disease¶
FOLFIRINOX (median survival 11 mo), gemcitabine, or NAPOLI-3 regimens. PARP inhibitors for BRCA/MSI tumors. Supportive care for pain and malabsorption.
8. PROGNOSIS & COMPLICATIONS¶
5-year survival: 13% overall. Complications include biliary obstruction, sepsis, and cachexia. Metastatic disease has median survival 6–12 mo. Early detection and molecular profiling improve outcomes.
8.1 Survival Rates¶
Localized: 44%, regional: 16%, metastatic: 3.2%. 1-year survival for metastatic disease improving to ~2 years with NAPOLI-3.
8.2 Complications¶
Biliary obstruction, vascular thrombosis, malabsorption, and cachexia. 10–15% develop diabetes mellitus or hyperglycemia.
9. SPECIAL CONSIDERATIONS¶
Genetic counseling for BRCA1/2 carriers. Obesity management (BMI ≥ 30 doubles risk). Avoid sugary drinks. Monitor for diabetes in high-risk patients. PARP inhibitors for BRCA/MSI tumors.
9.1 Genetic Counseling¶
BRCA1/2 carriers benefit from PARP inhibitors. Lynch syndrome patients require colonoscopic screening.
10. KEY POINTS & CLINICAL PEARLS¶
- Pancreatic cancer is the most lethal cancer with 13% 5-year survival. 2. Genetic testing is critical for high-risk patients (BRCA, Lynch syndrome). 3. Early detection via MRI/EUS is recommended for high-risk individuals. 4. FOLFIRINOX improves survival in resectable disease. 5. PARP inhibitors benefit BRCA/MSI tumors. 6. Supportive care for malabsorption (PERT) and pain management is essential.